Analysts’ Viewpoint
Rise in prevalence of spinal disorders and increase in geriatric population is driving the global spine biologics market. Surge in elderly population is expected to propel demand for innovative and effective treatments for spinal conditions such as degenerative disc disease and spinal stenosis. Rise in adoption of spine biologics, which offer regenerative and minimally invasive solutions for spinal disorders, are likely to bolster market expansion. Furthermore, integration of spine biologics with advanced surgical techniques, such as minimally invasive procedures and robotic-assisted surgeries, which offer patients enhanced outcomes and faster recovery times, are projected to drive the global spine biologics market size.
Surge in investment in research & development to improve the safety and efficacy of spine biologics treatments offers lucrative opportunities to market players. Spine biologics companies are focusing on strategic launches and collaborations to enhance product offerings and expand their global footprint.
Spine biologics include biomaterials that are used to treat spinal cord injuries, degenerative disc disorders, and bone fusion procedures. Inflammation, healing, and remodeling are the primary processes that it uses to drive growth of bone formation.
Development of biologics that support the repair and regeneration of cartilaginous and bony structures is now underway, while certain biologics are intended to be utilized as a person's natural bone graft replacement.
Some of the spine biologics market trends are technological advances in bone grafting treatments. For instance, in April 2022, Royal Biologics launched Advanced-Cell, an advanced fusion bone grafting system for use in orthopedics. Advanced-Cell provides users with the ability to provide an optimal live cellular grafting option, combined with next-generation bone grafting technology to deliver point-of-care in a low cost bundle option.
Increase in geriatric population and rise in frequency of spine abnormalities are propelling the market. Surge in preference for minimally invasive procedures, rise in incidence of degenerative spine disorders, and surge in treatment cost are driving market expansion. Benefits of biologics such as faster recovery, minimal postoperative time, and ability to activate cellular growth is another major factor fueling global spine biologics market demand.
However, unfavorable reimbursement scenario, higher bone graft costs, and ethical concerns are likely to restrain market growth to some extent.
Development and commercialization of advanced stem cell therapies is also bolstering the market. Stem cells have shown promising potential in promoting tissue regeneration and improving patient outcomes in spinal fusion surgeries.
Various companies have developed innovative bone graft substitutes using biologic materials. For instance, in 2021, Medtronic offered INFUSE Bone Graft, which utilizes a recombinant human bone morphogenetic protein (rhBMP-2) to stimulate bone growth in spinal fusion surgeries. This product eliminates the need for harvesting bone from the patient's body and has shown positive clinical outcomes.
Adoption of these bone graft substitutes is increasing, as these offer advantages such as ease of use, reduced risk of infection, and improved patient outcomes. Research and development efforts are focused on enhancing the efficacy and safety of spine biologics, which is expected to provide opportunities for companies to develop novel products and therapies during the forecast period.
The COVID-19 pandemic has had a significant impact on the market. The pandemic resulted in a temporary decline in the market due to the postponement or cancellation of non-emergency elective surgeries. A number of healthcare systems redirected resources to prioritize the treatment of COVID-19 patients, leading to reduced demand for spine biologics.
Supply chain disruptions caused challenges in the production and distribution of spine biologics. Manufacturing delays, transportation constraints, and import/export restrictions led to potential shortages and limited availability of these products.
Stem cell treatments, which have shown promise in spinal fusion surgeries, experienced reduced demand as healthcare facilities focused on COVID-19 management. Limited availability of stem cell-based products and restrictions on research activities further hampered their utilization.
However, as vaccination efforts expanded and healthcare systems adapted to the pandemic, the spine biologics market started to recover. Resumption of elective surgeries and growing demand for advanced spinal treatments provided opportunities for market growth. Ongoing research and development efforts in the field of spine biologics are expected to fuel market expansion in the post-pandemic period.
In terms of product, the bone allografts segment held largest global spine biologics market share in 2022. The trend is expected to continue during the forecast period. This is ascribed to factors such as rise in prevalence of spinal disorders and advancements in processing techniques.
Spinal allografts provide structural support and aid in fusion, making them a crucial component in spinal fusion surgeries. Companies such as Medtronic, NuVasive, and Globus Medical have been key players in the spinal biologics market, offering a range of allograft products to address the needs of patients with spinal disorders.
Based on surgery type, the minimally invasive surgery segment dominated the global market in 2022. This is ascribed to advantages such as reduced tissue damage, shorter hospital stay, and faster recovery. As more patients and surgeons prefer minimally invasive approaches, the demand for spine biologics that complement these procedures is expected to increase.
In terms of end-user, the hospitals segment accounted for leading share of the global spine biologics market in 2022. Hospitals serve as major healthcare providers and have the infrastructure and resources to perform complex spinal procedures that often require the use of biologics.
Hospitals typically have specialized spine centers and multidisciplinary teams of healthcare professionals dedicated to spinal treatments. Their expertise, coupled with the availability of advanced imaging and surgical facilities, positions hospitals as key players in the spine biologics market.
According to the global market report, North America accounted for significant share of the global market in 2022. This is ascribed to large geriatric population, increase in adoption of minimally invasive procedure, and rise in prevalence of spine disorders such as spondylolisthesis, spinal stenosis, and disc-related issue.
According to the American Association of Neurological Surgeons, an estimated 17,000 new cases of spinal cord injury are reported in the U.S. every year. Thus, a large spinal cord injury population is likely to drive demand for treatment of disorders, wherein spinal biologics plays an important role in diagnosis.
As per the market forecast, Asia Pacific is expected to witness significant spine biologics market expansion during the forecast period. This is ascribed to increase in geriatric population, rise in prevalence of spinal disorders, growing healthcare infrastructure, and improving access to advanced spinal treatments in countries such as China, India, and Japan.
The report concludes with the company profiles section that includes key information about the major players. Companies focus on strategies such as new product launches, mergers, and partnerships & collaborations to compete in the marketplace.
Major spine biologics companies are Johnson & Johnson (Depuy Synthes), Orthofix Medical, Inc., Stryker Corporation, Zimmer Biomet, Arthrex, Inc., Exactech, Inc., Spine Wave, Inc., Medtronic plc, and NuVasive, Inc.
Prominent players have been profiled in the spine biologics market report based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.
| Attribute | Detail |
|---|---|
|
Size in 2022 |
US$ 2.4 Bn |
|
Forecast (Value) in 2031 |
US$ 3.5 Bn |
|
Growth Rate (CAGR) |
4.1% |
|
Forecast Period |
2023-2031 |
|
Historical Data Available for |
2017-2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global industry was valued at US$ 2.4 Bn in 2022.
It is projected to reach more than US$ 3.5 Bn by 2031.
The market is anticipated to grow at a CAGR of 4.1% from 2023 to 2031.
Rise in prevalence of spinal disorders, increase in geriatric population, and technological advances in bone grafting treatments are driving the market.
The minimally invasive surgery segment accounted for significant share in 2022.
North America is expected to account for the largest share of the market from 2023 to 2031.
Johnson and Johnson (Depuy Synthes), Orthofix Medical, Inc., Stryker Corporation, Zimmer Biomet, Arthrex, Inc., Exactech, Inc., Spine Wave, Inc., Medtronic plc, and NuVasive, Inc. are the prominent players in the market.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Spine Biologics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Spine Biologics Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Forces Analysis
5. Key Insights
5.1. Technological Advancements
5.2. Reimbursement Scenario by Region/Globally
5.3. Regulatory Scenario by Region/Globally
5.4. Pipeline Analysis
5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Spine Biologics Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2017-2031
6.3.1. Bone Allografts
6.3.2. Bone Graft Substitute
6.3.3. Platelet Rich Plasma
6.3.4. Bone Marrow Aspirate Therapy
6.3.5. Demineralized Bone Matrix (DBM)
6.3.6. Others
6.4. Market Attractiveness Analysis, by Product
7. Global Spine Biologics Market Analysis and Forecast, by Surgery Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Surgery Type, 2017-2031
7.3.1. Minimally Invasive Surgery
7.3.2. Open Surgery
7.4. Market Attractiveness Analysis, by Surgery Type
8. Global Spine Biologics Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application, 2017-2031
8.3.1. Spinal Fusion
8.3.2. Spinal Non-union & Fracture Repair
8.3.3. Degenerative Disc Disease Treatment
8.3.4. Other Applications
8.4. Market Attractiveness Analysis, by Application
9. Global Spine Biologics Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017-2031
9.3.1. Hospitals
9.3.2. Spinal Surgery Centers
9.3.3. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Spine Biologics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017-2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Spine Biologics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017-2031
11.2.1. Bone Allografts
11.2.2. Bone Graft Substitute
11.2.3. Platelet Rich Plasma
11.2.4. Bone Marrow Aspirate Therapy
11.2.5. Demineralized Bone Matrix (DBM)
11.2.6. Others
11.3. Market Value Forecast, by Surgery Type, 2017-2031
11.3.1. Minimally Invasive Surgery
11.3.2. Open Surgery
11.4. Market Value Forecast, by Application, 2017-2031
11.4.1. Spinal Fusion
11.4.2. Spinal Non-union & Fracture Repair
11.4.3. Degenerative Disc Disease Treatment
11.4.4. Other Applications
11.5. Market Value Forecast, by End-user, 2017-2031
11.5.1. Hospitals
11.5.2. Spinal Surgery Centers
11.5.3. Others
11.6. Market Value Forecast, by Country, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product
11.7.2. By Surgery Type
11.7.3. By Application
11.7.4. By End-user
11.7.5. By Country
12. Europe Spine Biologics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017-2031
12.2.1. Bone Allografts
12.2.2. Bone Graft Substitute
12.2.3. Platelet Rich Plasma
12.2.4. Bone Marrow Aspirate Therapy
12.2.5. Demineralized Bone Matrix (DBM)
12.2.6. Others
12.3. Market Value Forecast, by Surgery Type, 2017-2031
12.3.1. Minimally Invasive Surgery
12.3.2. Open Surgery
12.4. Market Value Forecast, by Application, 2017-2031
12.4.1. Spinal Fusion
12.4.2. Spinal Non-union & Fracture Repair
12.4.3. Degenerative Disc Disease Treatment
12.4.4. Other Applications
12.5. Market Value Forecast, by End-user, 2017-2031
12.5.1. Hospitals
12.5.2. Spinal Surgery Centers
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Product
12.7.2. By Surgery Type
12.7.3. By Application
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Spine Biologics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017-2031
13.2.1. Bone Allografts
13.2.2. Bone Graft Substitute
13.2.3. Platelet Rich Plasma
13.2.4. Bone Marrow Aspirate Therapy
13.2.5. Demineralized Bone Matrix (DBM)
13.2.6. Others
13.3. Market Value Forecast, by Surgery Type, 2017-2031
13.3.1. Minimally Invasive Surgery
13.3.2. Open Surgery
13.4. Market Value Forecast, by Application, 2017-2031
13.4.1. Spinal Fusion
13.4.2. Spinal Non-union & Fracture Repair
13.4.3. Degenerative Disc Disease Treatment
13.4.4. Other Applications
13.5. Market Value Forecast, by End-user, 2017-2031
13.5.1. Hospitals
13.5.2. Spinal Surgery Centers
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Product
13.7.2. By Surgery Type
13.7.3. By Application
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Spine Biologics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017-2031
14.2.1. Bone Allografts
14.2.2. Bone Graft Substitute
14.2.3. Platelet Rich Plasma
14.2.4. Bone Marrow Aspirate Therapy
14.2.5. Demineralized Bone Matrix (DBM)
14.2.6. Others
14.3. Market Value Forecast, by Surgery Type, 2017-2031
14.3.1. Minimally Invasive Surgery
14.3.2. Open Surgery
14.4. Market Value Forecast, by Application, 2017-2031
14.4.1. Spinal Fusion
14.4.2. Spinal Non-union & Fracture Repair
14.4.3. Degenerative Disc Disease Treatment
14.4.4. Other Applications
14.5. Market Value Forecast, by End-user, 2017-2031
14.5.1. Hospitals
14.5.2. Spinal Surgery Centers
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Product
14.7.2. By Surgery Type
14.7.3. By Application
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Spine Biologics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product, 2017-2031
15.2.1. Bone Allografts
15.2.2. Bone Graft Substitute
15.2.3. Platelet Rich Plasma
15.2.4. Bone Marrow Aspirate Therapy
15.2.5. Demineralized Bone Matrix (DBM)
15.2.6. Others
15.3. Market Value Forecast, by Surgery Type, 2017-2031
15.3.1. Minimally Invasive Surgery
15.3.2. Open Surgery
15.4. Market Value Forecast, by Application, 2017-2031
15.4.1. Spinal Fusion
15.4.2. Spinal Non-union & Fracture Repair
15.4.3. Degenerative Disc Disease Treatment
15.4.4. Other Applications
15.5. Market Value Forecast, by End-user, 2017-2031
15.5.1. Hospitals
15.5.2. Spinal Surgery Centers
15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Product
15.7.2. By Surgery Type
15.7.3. By Application
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2022
16.3. Company Profiles
16.3.1. Johnson And Johnson (Depuy Synthes)
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Orthofix Medical Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Stryker Corporation
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Zimmer Biomet
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Arthrex, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Exactech, Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Spine Wave, Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Medtronic plc
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. NuVasive, Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
List of Tables
Table 01: Global Spine Biologics Market Value (US$ Mn) Forecast, by Product, 2022 and 2031
Table 02: Global Spine Biologics Market Value (US$ Mn) Forecast, by Surgery Type, 2017-2031
Table 03: Global Spine Biologics Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 04: Global Spine Biologics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 05: Global Spine Biologics Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 06: North America Spine Biologics Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 07: North America Spine Biologics Market Value (US$ Mn) Forecast, by Surgery Type, 2017-2031
Table 08: North America Spine Biologics Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 09: North America Spine Biologics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 10: North America Biologics Market Value Share Analysis, by Country, 2022 and 2031
Table 11: Europe Spine Biologics Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 12: Europe Spine Biologics Market Value (US$ Mn) Forecast, by Surgery Type, 2017-2031
Table 13: Europe Spine Biologics Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 14: Europe Spine Biologics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 15: Asia Pacific Spine Biologics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 16: Asia Pacific Spine Biologics Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 17: Asia Pacific Spine Biologics Market Value (US$ Mn) Forecast, by Surgery Type, 2017-2031
Table 18: Asia Pacific Spine Biologics Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 19: Asia Pacific Spine Biologics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 20: Latin America Spine Biologics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 21: Latin America Spine Biologics Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 22: Latin America Spine Biologics Market Value (US$ Mn) Forecast, by Surgery Type, 2017-2031
Table 23: Latin America Spine Biologics Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 24: Latin America Spine Biologics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 25: Middle East & Africa Spine Biologics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 26: Middle East & Africa Spine Biologics Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 27: Middle East & Africa Spine Biologics Market Value (US$ Mn) Forecast, by Surgery Type, 2017-2031
Table 28: Middle East & Africa Spine Biologics Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 29: Middle East & Africa Spine Biologics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
List of Figures
Figure 01: Global Spine Biologics Market Value Share Analysis, by Product, 2022 and 2031
Figure 02: Global Spine Biologics Market Attractiveness Analysis, Product, 2023-2031
Figure 03: Global Spine Biologics Market Revenue (US$ Mn), by Bone Allografts, 2017-2031
Figure 04: Global Spine Biologics Market Revenue (US$ Mn), by Bone Graft Substitute, 2017-2031
Figure 05: Global Spine Biologics Market Revenue (US$ Mn), by Platelet Rich Plasma, 2017-2031
Figure 06: Global Spine Biologics Market Revenue (US$ Mn), by Bone Marrow Aspirate Therapy, 2017-2031
Figure 07: Global Spine Biologics Market Revenue (US$ Mn), by Demineralized Bone Matrix (DBM), 2017-2031
Figure 08: Global Spine Biologics Market Revenue (US$ Mn), by Others, 2017-2031
Figure 09: Global Spine Biologics Market Value Share Analysis, by Surgery Type, 2022 and 2031
Figure 10: Global Spine Biologics Market Attractiveness Analysis, by Surgery Type, 2023-2031
Figure 11: Global Spine Biologics Market Revenue (US$ Mn), by Minimally Invasive Surgery, 2017-2031
Figure 12: Global Spine Biologics Market Revenue (US$ Mn), by Open Surgery, 2017-2031
Figure 13: Global Spine Biologics Market Value Share Analysis, by Application, 2022 and 2031
Figure 14: Global Spine Biologics Market Attractiveness Analysis, Application, 2023-2031
Figure 15: Global Spine Biologics Market Revenue (US$ Mn), by Spinal Fusion, 2017-2031
Figure 16: Global Spine Biologics Market Revenue (US$ Mn), by Spinal Non-union & Fracture Repair, 2017-2031
Figure 17: Global Spine Biologics Market Revenue (US$ Mn), by Degenerative Disc Disease Treatment, 2017-2031
Figure 18: Global Spine Biologics Market Revenue (US$ Mn), by Other Applications, 2017-2031
Table 19: Europe Spine Biologics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Figure 20: Global Spine Biologics Market Attractiveness Analysis, End-user, 2023-2031
Figure 21: Global Spine Biologics Market Revenue (US$ Mn), by Hospitals, 2017-2031
Figure 22: Global Spine Biologics Market Revenue (US$ Mn), by Spinal Surgery Centers, 2017-2031
Figure 23: Global Spine Biologics Market Revenue (US$ Mn), by Others
Figure 24: Global Spine Biologics Market Value Share Analysis, by Region, 2022 and 2031
Figure 25: Global Spine Biologics Market Attractiveness Analysis, by Region, 2023-2031
Figure 26: North America Spine Biologics Market Value (US$ Mn) Forecast, 2017-2031
Figure 27: North America Spine Biologics Market Value Share Analysis, by Country, 2022 and 2031
Figure 28: North America Spine Biologics Market Attractiveness Analysis, by Country, 2023-2031
Figure 29: North America Spine Biologics Market Value Share Analysis, by Product, 2022 and 2031
Figure 30: North America Spine Biologics Market Attractiveness Analysis, Product, 2023-2031
Figure 31: North America Spine Biologics Market Value Share Analysis, by Surgery Type, 2022 and 2031
Figure 32: North America Spine Biologics Market Attractiveness Analysis, Surgery Type, 2023-2031
Figure 33: North America Spine Biologics Market Value Share Analysis, by Application, 2022 and 2031
Figure 34: North America Spine Biologics Market Attractiveness Analysis, by Application, 2023-2031
Figure 35: North America Spine Biologics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 36: North America Spine Biologics Market Attractiveness Analysis, by End-user, 2023-2031
Figure 37: Europe Spine Biologics Market Value (US$ Mn) Forecast, 2017-2031
Figure 38: Europe Spine Biologics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 39: Europe Spine Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 40: Europe Spine Biologics Market Value Share Analysis, by Product, 2022 and 2031
Figure 41: Europe Spine Biologics Market Attractiveness Analysis, Product, 2023-2031
Figure 42: Europe Spine Biologics Market Value Share Analysis, by Surgery Type, 2022 and 2031
Figure 43: Europe Spine Biologics Market Attractiveness Analysis, by Surgery Type, 2023-2031
Figure 44: Europe Spine Biologics Market Value Share Analysis, by Application, 2022 and 2031
Figure 45: Europe Spine Biologics Market Attractiveness Analysis, by Application, 2023-2031
Figure 46: Europe Spine Biologics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 47: Europe Spine Biologics Market Attractiveness Analysis, by End-user, 2023-2031
Figure 48: Asia Pacific Spine Biologics Market Value (US$ Mn) Forecast, 2017-2031
Figure 49: Asia Pacific Spine Biologics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 50: Asia Pacific Spine Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 51: Asia Pacific Spine Biologics Market Value Share Analysis, by Product, 2022 and 2031
Figure 52: Asia Pacific Spine Biologics Market Attractiveness Analysis, Product, 2023-2031
Figure 53: Asia Pacific Spine Biologics Market Value Share Analysis, by Surgery Type, 2022 and 2031
Figure 54: Asia Pacific Spine Biologics Market Attractiveness Analysis, by Surgery Type, 2023-2031
Figure 55: Asia Pacific Spine Biologics Market Value Share Analysis, by Application, 2022 and 2031
Figure 56: Asia Pacific Spine Biologics Market Attractiveness Analysis, by Application, 2023-2031
Figure 57: Asia Pacific Spine Biologics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 58: Asia Pacific Spine Biologics Market Attractiveness Analysis, by End-user, 2023-2031
Figure 59: Latin America Spine Biologics Market Value (US$ Mn) Forecast, 2017-2031
Figure 60: Latin America Spine Biologics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 61: Latin America Spine Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 62: Latin America Spine Biologics Market Value Share Analysis, by Product, 2022 and 2031
Figure 63: Latin America Spine Biologics Market Attractiveness Analysis, Product, 2023-2031
Figure 64: Latin America Spine Biologics Market Value Share Analysis, by Surgery Type, 2022 and 2031
Figure 65: Latin America Spine Biologics Market Attractiveness Analysis, Surgery Type, 2023-2031
Figure 66: Latin America Spine Biologics Market Value Share Analysis, by Application, 2022 and 2031
Figure 67: Latin America Spine Biologics Market Attractiveness Analysis, by Application, 2023-2031
Figure 68: Latin America Spine Biologics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 69: Latin America Spine Biologics Market Attractiveness Analysis, by End-user, 2023-2031
Figure 70: Middle East & Africa Spine Biologics Market Value (US$ Mn) Forecast, 2017-2031
Figure 71: Middle East & Africa Spine Biologics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 72: Middle East & Africa Spine Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 73: Middle East & Africa Spine Biologics Market Value Share Analysis, by Product 2022 and 2031
Figure 74: Middle East & Africa Spine Biologics Market Attractiveness Analysis, Product, 2023-2031
Figure 75: Middle East & Africa Spine Biologics Market Value Share Analysis, by Surgery Type, 2022 and 2031
Figure 76: Middle East & Africa Spine Biologics Market Attractiveness Analysis, Surgery Type, 2023-2031
Figure 77: Middle East & Africa Spine Biologics Market Value Share Analysis, by Application, 2022 and 2031
Figure 78: Middle East & Africa Spine Biologics Market Attractiveness Analysis, by Application, 2023-2031
Figure 79: Middle East & Africa Spine Biologics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 80: Middle East & Africa Spine Biologics Market Attractiveness Analysis, by End-user, 2023-2031
Figure 81: Global Spine Biologics Market Share Analysis, by Company 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Spine Biologics Market
